In view of the therapeutic potential of EGFR-TKIs in EGFR-mutated advanced NSCLC, several scholars have explored the value of preoperative use of EGFR-TKIs in patients with resectable NSCLC with EGFR mutations. Here, EGFR is linked to non-small cell lung carcinoma.